Investment Rating - The report maintains a "Buy" rating for Yadea Group Holdings (1585 HK) with a target price raised to HKD 19.84, indicating a potential upside of 32.6% from the current price of HKD 14.96 [2][3][8]. Core Insights - Yadea Group is expected to benefit from the new national standards and the "trade-in" policy, which are anticipated to drive the two-wheeler industry into a new cycle. Despite a decline in revenue and net profit for 2024 due to inventory destocking and the transition between old and new standards, Yadea is positioned as an industry leader with enhanced technology, channels, and product strength [2][5]. - The company is focusing on high-end products, aiming for over 50% of its sales to come from this segment by 2025. The introduction of sodium-ion battery products is expected to enhance product competitiveness [5][10]. - Yadea's overseas sales are projected to grow significantly, with expectations of exporting 40,000 units in 2025, increasing to 160,000 units by 2027 [5][10]. Financial Summary - For 2024, Yadea's revenue is projected at RMB 28.236 billion, a decrease of 18.8% year-on-year, with a net profit of RMB 1.521 billion, down 51.8% [5][10]. - Revenue forecasts for 2025, 2026, and 2027 are RMB 37.865 billion, RMB 41.507 billion, and RMB 45.338 billion respectively, with net profits expected to be RMB 3.023 billion, RMB 3.518 billion, and RMB 3.967 billion [4][10]. - The gross profit margin is expected to improve from 15.2% in 2024 to 18.6% in 2025, reflecting a recovery in profitability [5][10].

Investment Rating - The report assigns a "Buy" rating for WuXi Biologics (2269.HK) based on its strong performance and growth potential in the biopharmaceutical sector [13]. Core Insights - The overall performance of the company meets expectations, with significant acceleration in the second half of the year driven by a recovery in the North American market, high growth in preclinical services (R&D), and strong demand for ADC projects [2][5]. - The company has a robust project and order reserve, indicating a solid foundation for sustained growth, with 151 new projects signed in 2024, a 14.4% increase from 2023 [4][5]. - The company operates a leading CRDMO platform with three long-term growth curves: Research (R), Development (D), and Manufacturing (M), which are expected to enhance its competitive edge [6]. Financial Performance Summary - In 2024, the company achieved total revenue of 18.675 billion yuan, a year-on-year increase of 9.6%, with non-COVID revenue growing by 13.1% [1][2]. - The gross profit for 2024 was 7.651 billion yuan, reflecting a gross margin of 41.0%, while net profit reached 3.945 billion yuan, a 10.5% increase [1][7]. - The adjusted net profit attributable to the parent company was 4.784 billion yuan, showing a 1.8% increase, with an adjusted net margin of 25.6% [1][7]. Revenue Breakdown - Revenue from North American clients was 10.696 billion yuan, a 32.5% increase, while revenue from Chinese clients decreased by 9.7% to 2.820 billion yuan [2][3]. - Preclinical service revenue grew by 30.7% to 7.062 billion yuan, while late-stage clinical development revenue declined by 3.2% to 7.485 billion yuan [3][4]. - Revenue from biopharmaceutical projects decreased by 2.6% to 14.731 billion yuan, while XDC project revenue surged by 106.9% to 3.944 billion yuan [3][4]. Future Projections - The company anticipates a revenue growth of 12-15% in 2025, with core business revenue expected to grow by 17-20% [5]. - Projected revenues for 2025-2027 are 21.361 billion yuan, 24.391 billion yuan, and 27.421 billion yuan, respectively, with net profits expected to reach 4.028 billion yuan, 4.639 billion yuan, and 5.280 billion yuan [7][8].

Investment Rating - The investment rating for the company is "Buy" with a target price raised to HKD 64.00, indicating a potential upside of 12.7% from the current price of HKD 56.80 [4][27]. Core Insights - The company's Q4 performance met expectations, with total revenue and adjusted net profit reaching RMB 35.4 billion and RMB 4.7 billion respectively, reflecting year-on-year growth of 9% and 8% [2][8]. - The report highlights the acceleration of commercialization for the company's AI product, "可灵", which has generated RMB 100 million in revenue as of February [8]. - Revenue growth is projected to continue, with expectations of a 12% increase in 2025, driven by e-commerce GMV growth of 13% and online marketing revenue growth of 14% [8]. Financial Overview - Revenue projections for the company are as follows: RMB 113.47 billion in 2023, RMB 126.90 billion in 2024, RMB 141.64 billion in 2025, RMB 152.94 billion in 2026, and RMB 164.07 billion in 2027, with corresponding year-on-year growth rates of 20.5%, 11.8%, 11.6%, 8.0%, and 7.3% [3][28]. - Net profit is expected to rise from RMB 10.27 billion in 2023 to RMB 28.59 billion in 2027, with adjusted net profit projected at RMB 20.16 billion in 2025 [3][28]. - The company's earnings per share (EPS) are forecasted to increase from RMB 2.31 in 2023 to RMB 6.55 in 2027, with a significant jump to RMB 4.60 in 2025 [3][28]. Market Performance - The stock has shown a year-to-date increase of 37.36% and has a market capitalization of approximately HKD 202.49 billion [6][8]. - The stock's 52-week high and low are HKD 66.35 and HKD 38.15 respectively, indicating a strong recovery from its lows [6]. Business Segments - E-commerce GMV grew by 14% year-on-year, with the number of active merchants increasing by over 25% [8]. - Online marketing revenue increased by 13%, primarily driven by external advertising, while live streaming revenue saw a slight decline of 2% [8]. - The local life services segment reported a significant increase, with monthly payment users and GMV growing by 52% and 100% respectively [8].

| 医药 | 收盘价 | | 目标价 | 潜在涨幅 | 2025 年 3 月 26 日 | | --- | --- | --- | --- | --- | --- | | 港元 | | 25.90 | 港元 25.00↑ | -3.5% | | | 药明生物 (2269 HK) | | | | | | 2H24 业绩复苏，RDM 三大业务端边际改善确定性较强，上调目标价 个股评级 中性 1 年股价表现 : FactSet 3/24 7/24 11/24 3/25 -40% -20% 0% 20% 40% 60% 80% 100% 120% 2269 HK 恒生指数 股份资料 | 52周高位 (港元) | 28.50 | | --- | --- | | 52周低位 (港元) | 10.26 | | 市值 (百万港元) | 106,372.34 | | 日均成交量 (百万) | 34.12 | | 年初至今变化 (%) | 47.49 | | 200天平均价 (港元) | 18.39 | | 资料来源 : FactSet | | 交银国际研究 公司更新 丁政宁 Ethan.Ding@bocomgroup.com ...

Investment Rating - The report maintains a "Buy" rating for Yadea Group Holdings (1585 HK) with a target price raised to HKD 19.84, indicating a potential upside of 32.6% from the current price of HKD 14.96 [2][3][8]. Core Insights - Yadea Group is expected to benefit from the new national standards and the "trade-in" policy, which are anticipated to drive the two-wheeler industry into a new cycle. Despite a decline in revenue and net profit for 2024 due to inventory destocking and the transition between old and new standards, Yadea is positioned as an industry leader with enhanced technology, channels, and product strength [2][5]. - The company is focusing on high-end products, aiming for over 50% of its sales to come from this segment by 2025. The introduction of sodium-ion battery products is expected to enhance product competitiveness [5][10]. - Yadea's overseas sales are projected to grow significantly, with expectations of exporting 40,000 units in 2025, 80,000 in 2026, and 160,000 in 2027 [5][10]. Financial Summary - For 2024, Yadea's revenue is projected at RMB 28.236 billion, a decrease of 18.8% year-on-year, with a net profit of RMB 1.521 billion, down 51.8% [5][10]. - Revenue forecasts for 2025, 2026, and 2027 are RMB 37.865 billion, RMB 41.507 billion, and RMB 45.338 billion respectively, with net profits expected to be RMB 3.023 billion, RMB 3.518 billion, and RMB 3.967 billion [4][10]. - The gross profit margin is expected to improve to 18.6% in 2025, with a gradual increase to 19.5% by 2027 [4][10].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a price increase of over 15% in the next 6-12 months [4]. Core Insights - The company achieved a total revenue of 24.755 billion RMB in 2024, representing a year-on-year growth of 4.8%. The fourth quarter revenue was 6.489 billion RMB, up 10.4% year-on-year. However, the net profit attributable to shareholders was 1.144 billion RMB, down 1.7% year-on-year [2][4]. - The clean energy segment remains a key growth driver, with revenues of 17.183 billion RMB, a 15.3% increase year-on-year, driven by rising demand for LNG and industrial gases [2]. - The onshore business continues to lead in its niche, generating 11.67 billion RMB in revenue with new orders of 10.08 billion RMB, supported by strong natural gas market dynamics [2]. - The offshore business is entering a performance realization phase, with revenues of 4.66 billion RMB, a significant increase of 108.4% year-on-year, and new orders exceeding 10.86 billion RMB [3]. - Hydrogen energy business is steadily acquiring new contracts, with revenues of 850 million RMB, up 21.7% year-on-year, and new orders also at 850 million RMB [3]. - The chemical segment faced challenges, with revenues declining by 29.4% to 3.116 billion RMB, while the liquid food segment grew by 3.7% to 4.451 billion RMB [4]. Summary by Sections Performance Overview - In 2024, the company reported total revenue of 24.755 billion RMB, a 4.8% increase from the previous year, with a net profit of 1.144 billion RMB, down 1.7% [2][4]. Business Analysis - Clean Energy: Revenue of 17.183 billion RMB, up 15.3% year-on-year, driven by increased demand for LNG and industrial gases [2]. - Onshore Business: Revenue of 11.67 billion RMB with new orders of 10.08 billion RMB, supported by strong market demand [2]. - Offshore Business: Revenue of 4.66 billion RMB, up 108.4% year-on-year, with new orders exceeding 10.86 billion RMB [3]. - Hydrogen Energy: Revenue of 850 million RMB, up 21.7% year-on-year, with new orders also at 850 million RMB [3]. - Chemical Segment: Revenue of 3.116 billion RMB, down 29.4% year-on-year [4]. - Liquid Food Segment: Revenue of 4.451 billion RMB, up 3.7% year-on-year [4]. Profit Forecast and Valuation - The company is expected to achieve net profits of 1.38 billion RMB, 1.67 billion RMB, and 1.97 billion RMB for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 9.5, 7.8, and 6.6 [4].

[Table_MainInfo] 公司研究/食品 证券研究报告 农夫山泉（9633.HK）年度报告 2025 年 03 月 26 日 [Table_InvestInfo] 投资评级 优于大市 维持 股票数据 | 3[Table_StockInfo 月 26 日收盘价（HKD] ） | 33.70 | | --- | --- | | 52 周股价波动（HKD） | 32.00-39.50 | | 总股本（亿股） | 112.46 | 总市值/流通市值（亿 HKD） 《继续看好茶饮料业务高增长及未来盈利 能 力持续向上》2024.01.18 市场表现 [Table_QuoteInfo] 恒生指数对比 1M 2M 3M 绝对涨幅（%） 9.05 2.65 6.52 相对涨幅（%） 9.62 -13.45 -11.85 资料来源：海通证券研究所 逆境中收入平稳，盈利维持高水平，期待 25 年包装水复苏 [Table_Summary] 投资要点： 主要财务数据及预测 相关研究 [Table_ReportInfo] 《农夫山泉（9633）24 年半年报点评：短期 网络事件致包装水业务承压，茶饮料继续高增 驱动整体业绩稳健 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [4][10]. Core Insights - The company has shown steady revenue growth, achieving an annual revenue of 126.9 billion yuan in 2024, a year-on-year increase of 11.8%, with a net profit margin of 14% [1]. - The AI-driven content platform is rapidly commercializing, with significant user growth and increased engagement, leading to a cumulative revenue of over 100 million yuan from its AI product by February 2025 [2]. - The online marketing business has seen a revenue increase of 20.1% year-on-year, driven by enhanced AIGC capabilities, while the e-commerce segment reported a GMV of 1.39 trillion yuan, up 17.3% year-on-year [3]. Financial Performance Summary - In 2024, the company achieved a gross profit margin of 54.6%, with an adjusted net profit of 17.72 billion yuan, reflecting a 72.5% year-on-year increase [1]. - The projected adjusted net profits for 2025-2027 are 20.08 billion yuan, 24.62 billion yuan, and 28.72 billion yuan, respectively [4]. - The company’s revenue is expected to grow from 141.91 billion yuan in 2025 to 170.40 billion yuan by 2027, with a decreasing growth rate from 11.83% to 8.77% [6][9].

Investment Rating - The report does not specify a clear investment rating for the company [1] Core Insights - The company reported a revenue of 428.12 million RMB for 2024, with a projected revenue growth rate of 63.65% for 2025, reaching 700.62 million RMB [2][9] - The company is set to launch its product CM310, which is expected to significantly contribute to revenue growth in the coming years [7] - The company has received regulatory approvals for its product, including three indications for the drug Siponimod, which is anticipated to drive sales [7] - Multiple licensing agreements have been established to accelerate global development and commercialization of its drug candidates, enhancing the company's market position [7] - The company has developed a comprehensive technology platform for drug development, covering various therapeutic areas including immunology and oncology [7] Financial Projections - Revenue projections for the company are as follows: 2025E at 700.62 million RMB, 2026E at 1,471.31 million RMB, and 2027E at 2,662.34 million RMB, indicating a strong growth trajectory [2][9] - The net profit attributable to the parent company is expected to improve from a loss of 555.68 million RMB in 2025E to a profit of 193.03 million RMB in 2027E [2][9] - The earnings per share (EPS) is projected to turn positive by 2027, with an EPS of 0.69 RMB [2][9]

2025 年 3 月 26 日 公司研究 临床前收入快速恢复，整体项目数稳步提升 ——药明生物（2269.HK）2024 年年报点评 研发技术能力强，对外授权增厚利润。公司多个技术平台赋能客户多样化需求， 目前管线内有 313 个 first-in-class 项目，151 个双抗/多抗项目以及 194 个 ADC 项目。公司 TCE 平台开发能力已得到多方认可，基于该平台开发的产品被授权 给默沙东/GSK 等海外公司，且 Medigene AG 也和公司达成战略研究服务合作， 开发 TCR-TCE 疗法。公司技术平台已赋能 50+具里程碑付款及销售分成潜力的 项目，R 技术平台有权获得总额约为 1.4 亿美元的近期付款，潜在总交易金额超 过 23 亿美元，将增厚公司未来利润。 盈利预测、估值与评级：考虑到全球大分子 CDMO 竞争加剧，以及地缘政治影 响，下调 25-26 年归母净利润预测为 42.8/49.3 亿元（前值为 47.4/53.9 亿元， 分别下调 9.7%/8.5%），新增 27 年归母净利润预测为 57.5 亿元，对应 PE 为 23/20/17 倍。公司是我国大分子 CDMO 龙头，且技 ...